Entering text into the input field will update the search result below

AptarGroup: There Is A Lot Of Room For Growth

May 03, 2022 10:12 PM ETAptarGroup, Inc. (ATR)1 Comment
Carles Diaz Caron profile picture
Carles Diaz Caron


  • Net sales increased over the years thanks to steady acquisitions. Growth has slowed during the second half of 2021 but accelerated again during the first quarter of 2022.
  • The company has high exposure in Europe, leading the price to fall by 27% due to the Ukrainian war.
  • Debt has increased in recent years, which will limit future growth.
  • The dividend cash payout ratio is very low, allowing the company high capital expenditures and acquisitions.
  • This is a buy-and-hold for the long-run company.

Equipo médico y medicamentos para el tratamiento bronquial para el asma. Nebulizador de inhalación de aerosol, inhalador médico de aerosol para el asma, espaciador, nebulosa, antiinflamatorios para controlar el asma. Cura para el asma bronquio, concepto

Zolotaosen/iStock via Getty Images

Investment thesis

AptarGroup's (NYSE:ATR) growth has slowed over the second half of 2021. Still, net sales increased by 8.78% year over year during the first quarter of 2022 while profit margins are high and stable, and the company

This article was written by

Carles Diaz Caron profile picture
Subscribe for an average ~14% return per year according to Tipranks. I am a long-term Dividend Growth Investor always looking for new opportunities in the stock market since 2015. In order to find good deals in the stock market, I look for companies that are going through a bad time and carefully assess the chances that the financial situation will return to the path of profitability and growth. My objective is to find stocks that can be bought and held for many years and try to get them for the lowest price possible during temporary headwinds. For me, the most important aspects when analyzing a stock's turnaround chances are that the company's products are essential to a big portion of the population, healthy and stable profit margins, a sustainable debt and dividend, and a long-term trend that suggests the products and services offered will continue to be essential for the decades to come.

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Comments (1)

GreenGrowthGeek profile picture
Aptar's new partnership with TFFP will be very lucrative for both companies by 2023 at the latest. Mark my words. TFFP has the disruptive powder technology and Aptar has the best nasal delivery system. It's a symbiotic relationship.
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!

About ATR

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on ATR

Related Stocks

SymbolLast Price% Chg
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.